|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 205.7 EUR | -0.96% |
|
-1.25% | -14.11% |
| May. 08 | Certain Shares of Sartorius Stedim Biotech S.A. are subject to a Lock-Up Agreement Ending on 8-MAY-2024. | CI |
| Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
Sartorius Stedim Biotech provides earnings guidance for the full year 2022. The company expects Sales revenue to increase by 14% to 18% with sustained high profitability.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.11% | 21.56B | |
| -4.84% | 182B | |
| +0.56% | 110B | |
| -3.35% | 68.11B | |
| +2.39% | 50.53B | |
| +9.36% | 44.8B | |
| +2.70% | 40.7B | |
| +3.43% | 26.53B | |
| +13.67% | 25.02B | |
| -0.32% | 24.96B |
SARTORIUS STEDIM BIOTECH 
